- Home
- PLUR vs DYAI Comparison
PLUR vs DYAI Comparison
Compare PLUR & DYAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLUR
- DYAI
- Stock Information
- Founded
- PLUR 2001
- DYAI 1979
- Country
- PLUR Israel
- DYAI United States
- Employees
- PLUR N/A
- DYAI N/A
- Industry
- PLUR Biotechnology: Biological Products (No Diagnostic Substances)
- DYAI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PLUR Health Care
- DYAI Health Care
- Exchange
- PLUR Nasdaq
- DYAI Nasdaq
- Market Cap
- PLUR 36.9M
- DYAI 30.2M
- IPO Year
- PLUR N/A
- DYAI 2004
- Fundamental
- Price
- PLUR $3.90
- DYAI $1.13
- Analyst Decision
- PLUR Strong Buy
- DYAI Strong Buy
- Analyst Count
- PLUR 1
- DYAI 2
- Target Price
- PLUR $12.00
- DYAI $4.50
- AVG Volume (30 Days)
- PLUR 11.1K
- DYAI 83.4K
- Earning Date
- PLUR 11-11-2025
- DYAI 11-12-2025
- Dividend Yield
- PLUR N/A
- DYAI N/A
- EPS Growth
- PLUR N/A
- DYAI N/A
- EPS
- PLUR N/A
- DYAI N/A
- Revenue
- PLUR $1,336,000.00
- DYAI $4,135,078.00
- Revenue This Year
- PLUR $97.38
- DYAI $34.23
- Revenue Next Year
- PLUR $293.97
- DYAI $19.57
- P/E Ratio
- PLUR N/A
- DYAI N/A
- Revenue Growth
- PLUR 309.82
- DYAI 129.20
- 52 Week Low
- PLUR $3.33
- DYAI $0.71
- 52 Week High
- PLUR $7.13
- DYAI $2.20
- Technical
- Relative Strength Index (RSI)
- PLUR 41.43
- DYAI 51.99
- Support Level
- PLUR $3.60
- DYAI $1.07
- Resistance Level
- PLUR $4.00
- DYAI $1.21
- Average True Range (ATR)
- PLUR 0.19
- DYAI 0.10
- MACD
- PLUR -0.01
- DYAI -0.00
- Stochastic Oscillator
- PLUR 29.70
- DYAI 44.84
About PLUR Pluri Inc.
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.
About DYAI Dyadic International Inc.
Dyadic International Inc is a worldwide biotechnology platform company. It has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.